Celecoxib induces epithelial-mesenchymal transition in epithelial ovarian cancer cells via regulating ZEB1 expression

详细信息    查看全文

• 作者：Ruihan Liu ; Jingfang Zheng ; Chao Li ; Yingxin Pang…
• 关键词：Celecoxib ; Ovarian cancer ; EMT ; ZEB1
• 刊名：Archives of Gynecology and Obstetrics
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：291
• 期：6
• 页码：1361-1369
• 全文大小：4,115 KB
• 参考文献：1.Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10鈥?9View Article PubMed
  2.Parikh A, Lee C, Peronne J, Marchini S, Baccarini A (2014) microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun 5:2977View Article PubMed Central PubMed
  3.Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C (2009) Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol 99(7):424鈥?27View Article PubMed
  4.Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation and cancer. Cell 140(6):883鈥?99View Article PubMed Central PubMed
  5.Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular and molecular biology. Annu Rev Biochem 69:145鈥?82View Article PubMed
  6.Lim BJ, Jung SS, Choi SY, Lee CS (2010) Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance. Mol Med Rep 3(1):43鈥?9PubMed
  7.Lee JM, Mao JT, Krysan K, Dubinett SM (2007) Significance of cyclooxygenase-2 in prognosis targeted therapy and chemoprevention of NSCLC. Future Oncol 3(2):149鈥?53View Article PubMed
  8.Jang JT, Jeon KH, Jung KH (2009) Cyclooxygenase-2 expression related to the epithelial-mesenchymal transition in human colon cancers. Yonsei Med J 50(6):818鈥?24View Article PubMed Central PubMed
  9.Gr枚sch S, Maier TJ, Schiffmann S, Geisslinger G (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98(11):736鈥?47View Article PubMed
  10.Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R (2007) Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol 2(4):299鈥?05View Article PubMed
  11.Jakobsen A, Mortensen JP, Bisgaard C, Lindebjerg J, Rafaelsen SR (2008) A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial. Int J Colorectal Dis 23(3):251鈥?55View Article PubMed
  12.Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ (2008) Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 14(7):2095鈥?101View Article PubMed
  13.Reyners AK, de Munck L, Erdkamp FL, Smit WM, Hoekman K (2012) A randomized phase II study investigating the additional of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Ann Oncol 23(11):2896鈥?902View Article PubMed
  14.Legge L, Paglia A, D鈥橝sta M, Fuoco G, Scambia G (2011) Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC Cancer 11:214View Article PubMed Central PubMed
  15.Arend RC, Londo帽o-Joshi AI, Straughn JM Jr, Buchsbaum DJ (2013) The Wnt/尾-catenin pathway in ovarian cancer: a review. Gynecol Oncol 131(3):772鈥?79View Article PubMed
  16.Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420鈥?428View Article PubMed Central PubMed
  17.Garber K (2008) Epithelial-to-mesenchymal transition is important to metastasis, but questions remain. J Natl Cancer Inst 100(4):232鈥?, 239
  18.Vergara Daniele, Merlot Benjamin, Lucot Jean-Philippe, Collinet Pierre, Vinatier Denis, Fournier Isabelle (2010) Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 291(1):59鈥?6View Article PubMed
  19.Wang ZL, Fan ZQ, Jiang HD, Qu JM (2013) Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis 34(3):638鈥?46View Article PubMed
  20.Tse Joyce C, Kalluri Raghu (2007) Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101(4):816鈥?29View Article PubMed
  21.Cheng Jung-Chien, Auersperg Nelly, Leung Peter CK (2012) EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? PLoS One 7(3):e34071View Article PubMed Central PubMed
  22.Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871鈥?90View Article PubMed
  23.Shao M, Cao L, Shen L, Satpathy M, Chelladurai B (2009) Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 69(24):9192鈥?201View Article PubMed
  24.Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22(7):894鈥?07View Article PubMed Central PubMed
  25.Sun N, Zhang Q, Xu C, Zhao Q, Ma Y (2014) Molecular regulation of ovarian cancer cell invasion. Tumour Biol. 15 Aug [Epub ahead of print]
  26.Yang Y, Ahn YH, Chen Y, Tan X, Guo L (2014) ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 124(6):2696鈥?708View Article PubMed Central PubMed
  27.Lee JY, Myung SK, Song YS (2013) Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies. Gynecol Oncol 129(3):613鈥?19View Article PubMed
  28.Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H (2001) Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J 15(9):1622鈥?624PubMed
  
• 作者单位：Ruihan Liu (1)
  Jingfang Zheng (1)
  Chao Li (2)
  Yingxin Pang (1)
  Qiaomei Zheng (1)
  Xiaoxuan Xu (1)
  Peishu Liu (1)
  
  1. Department of Obstetrics and Gynecology, Qilu Hospital of Shangdong University, No. 107 Wen Hua Xi Road, Jinan, 250012, Shandong, China
  2. Department of Neurosurgery, Qilu Hospital of Shangdong University, No. 107 Wen Hua Xi Road, Jinan, 250012, Shandong, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Gynecology
  Obstetrics and Perinatology
  Endocrinology
  Human Genetics
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0711

文摘

Purpose The purpose of our study was to investigate the therapeutic potential of Celecoxib for epithelial ovarian cancer, especially on cellular morphological changes, proliferation invasion and epithelial-mesenchymal transition (EMT). Method The MTT and transwell assays were performed to evaluate the effect of Celecoxib on proliferation and invasion ability of ovarian cancer cell lines, respectively. Western blot was carried out to detect the expression of epithelial phenotypes, E-cadherin and Keratin, and mesenchymal phenotypes, N-cadherin and Vimentin, as well as p-AKT, p-ERK and ZEB1. ZEB1 small-interfering RNA (siRNA) was used to downregulate the expression of ZEB1 to further inquiring into the downstream of Celecoxib-induced EMT. Results Cellular morphological assessment revealed that both A2780 and SKOV3 cells gradually appeared in the morphology of mesenchymal cells after Celecoxib treatment. The MTT assay demonstrated that celecoxib had no effect on cell proliferation. Transwell assay showed that Celecoxib significantly increased the cell invasion ability. Western blot data proved that the expression of E-cadherin and keratin was elevated, whereas the expression of N-cadherin and Vimentin was decreased in a dose-dependent manner compared with the untreated cells, the expression of p-AKT, p-ERK and ZEB1 was also obviously elevated. However, ZEB1 siRNA reversed Celecoxib-induced E-cadherin expression and N-cadherin expression, as well as cellular invasiveness. Conclusion Our results indicated that Celecoxib might induce EMT and increase cellular invasiveness in ovarian cancer cells in vitro, which also implied that it needed a comprehensive evaluation in preclinical researches before introducing Celecoxib into the clinical regimen.